Protecting and improving health for a population of approximately half a billion people, equal access to modern and efficient healthcare for all Europeans, disease prevention and response – these are just a few topics on the health agenda of the European Union.
But regarding pharmaceutical R&D, the EU is at risk of losing touch with the rest of the world, says EFPIA, the European Federation of Pharmaceutical Industries and Associations. In an interview with the German news portal Pharma Fakten EFPIA's Director General, Nathalie Moll, demands an “ambitious industrial strategy.”
Read more
Tens of thousands of cancer patients are at risk of contracting antibiotic resistant superbugs that could make chemotherapy...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.